Maternal phenylketonuria

Christopher Cunniff, Jaime L. Frias, Celia Kaye, John B. Moeschler, Susan R. Panny, Tracy L. Trotter, Felix De La Cruz, John Williams, James W. Hanson, Cynthia A. Moore, Michele Lloyd-Puryear, H. Eugene Hoyme, Rebecca S. Wappner, Lauri Hall

Producción científica: Short surveyrevisión exhaustiva

4 Citas (Scopus)

Resumen

Elevated maternal phenylalanine levels during pregnancy are teratogenic and may result in growth retardation, significant psychomotor handicaps, and birth defects in the offspring of unmonitored and untreated pregnancies. Women of childbearing age with all forms of phenylketonuria, including mild variants such as hyperphenylalaninemia, should receive counseling concerning their risks for adverse fetal effects optimally before conceiving. The best outcomes occur when strict control of maternal phenylalanine levels is achieved before conception and continued throughout the pregnancy.

Idioma originalEnglish (US)
Páginas (desde-hasta)427-428
Número de páginas2
PublicaciónPediatrics
Volumen107
N.º2
DOI
EstadoPublished - 2001
Publicado de forma externa

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Huella

Profundice en los temas de investigación de 'Maternal phenylketonuria'. En conjunto forman una huella única.

Citar esto